JP Morgan Cazenove started coverage on shares of Prosensa Holding (NYSE:RNA) in a research note issued on Tuesday, ARN reports. The firm set an “outperform” rating on the stock.
A number of other analysts have also recently weighed in on RNA. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Prosensa Holding in a research note to investors on Tuesday. They set an “overweight” rating on the stock. Separately, analysts at Citigroup Inc. initiated coverage on shares of Prosensa Holding in a research note to investors on Tuesday. They set a “buy” rating on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Prosensa Holding in a research note to investors on Tuesday. They set an “outperform” rating and a $35.00 price target on the stock.
Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $42.50.
Prosensa Holding (NYSE: RNA) traded up 5.30% on Tuesday, hitting $27.23. Prosensa Holding has a 52-week low of $16.97 and a 52-week high of $30.94. The stock’s 50-day moving average is currently $24.04. The company’s market cap is $789.7 million.
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (NYSE: RNA)-modulating, therapeutics for the treatment of genetic disorders.